OncologyKnife fightData as of 2026-09-04
Non-Small Cell Lung Cancer is one of the more crowded fields on the map: 30 companies in the clinic, ranking it 1st of 299 indications by competitor count. The median competitor is worth $1.1B, below the $1.20B median of the universe.
That gap is the crowding discount. When a field is deep the market pays less per company, because the same eventual revenue has to be split across more shots on goal.
No one owns the field: the largest company, JAZZ, holds only 20% of the $82.3B competing here.
$16.2B of allocated capital sits in Non-Small Cell Lung Cancer, 4th of 299 indications, and 3 of the 30 companies are pure plays that trade on this indication alone.
| Ticker | Company | Lead asset | Phase | Trials | Market cap | Pure play | Indications | Next catalyst |
|---|---|---|---|---|---|---|---|---|
| SMMT | Summit Therapeutics | ivonescimab | Phase 3 | 3 | $13.7B | No | 5 | 14 Nov 2026 |
| IBRX | ImmunityBio | N-803 | Phase 3 | 4 | $8.7B | No | 12 | 31 Dec 2026 |
| HCM | HUTCHMED (China) | Savolitinib | Phase 3 | 1 | $2.5B | No | 6 | No dated event |
| NUVB | Nuvation Bio | Taletrectinib | Phase 3 | 5 | $2.4B | No | 3 | 26 Oct 2026 |
| AVBP | ArriVent BioPharma | JAB-21822 | Phase 3 | 12 | $1.4B | No | 5 | No dated event |
| JAZZ | Jazz Pharmaceuticals | Zanidatamab | Phase 2 | 1 | $16.1B | No | 14 | 30 Sep 2026 |
| IOVA | Iovance Biotherapeutics | LN-145/LN-144 | Phase 2 | 1 | $3.9B | No | 6 | 23 Oct 2026 |
| RCUS | Arcus Biosciences | Zimberelimab | Phase 2 | 4 | $3.8B | No | 5 | 14 Nov 2026 |
| REPL | Replimune Group | RP1, intra-tumoral, oncolytic virus | Phase 2 | 1 | $1.3B | No | 4 | 31 Dec 2030 |
| CADL | Candel Therapeutics | aglatimagene besadenovec | Phase 2 | 1 | $992M | No | 2 | 30 Sep 2026 |
| DSGN | Design Therapeutics | Alectinib- Usual | Phase 2 | 2 | $941M | No | 6 | 31 Dec 2026 |
| VSTM | Verastem | VS-7375 | Phase 2 | 3 | $723M | No | 8 | 31 Dec 2026 |
| EIKN | Eikon Therapeutics | EIK1001 | Phase 2 | 2 | $593M | Yes | 1 | 23 Oct 2026 |
| AGEN | Agenus | Botensilimab | Phase 2 | 1 | $371M | No | 7 | 31 Dec 2026 |
Sorted by phase, then by market capitalisation. Ticker links open the company profile. Showing the 14 largest of the 30 companies competing in this indication. JAZZ holds 20% of the $82.3B competing in this indication.
Crowded and cheaply priced. Six or more competitors and a median company below the universe median.
Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.
See every Oncology indication on the map30 US-listed companies in the $100M to $20B market cap band run clinical programmes in Non-Small Cell Lung Cancer. The largest and most advanced are Summit Therapeutics (SMMT, ivonescimab, Phase 3); ImmunityBio (IBRX, N-803, Phase 3); HUTCHMED (China) (HCM, Savolitinib, Phase 3); Nuvation Bio (NUVB, Taletrectinib, Phase 3); ArriVent BioPharma (AVBP, JAB-21822, Phase 3). The table on this page lists the 14 largest of them.
Of the 30 clinical-stage programmes in Non-Small Cell Lung Cancer, 5 are in Phase 3 or filed, 12 are in mid-stage development and 13 are in early-stage development.
The median company developing a drug for Non-Small Cell Lung Cancer is worth $1.1B, against a median of $1.20B across the whole universe. $16.2B of allocated capital sits in the indication, ranking it 4th of 299.
The next dated catalyst in Non-Small Cell Lung Cancer is JAZZ on 30 Sep 2026. 26 dated events across the field fall in the next 12 months.
Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.
Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.
Back to the disease map